Tag Archives: gastric cancer

PD-L1 Inhibitor, avelumab, approved for Merkel cell carcinoma

Avelumab (Bavencio) is a PD-L1 inhibitor that was approved for the treatment of patients with metastatic Merkel cell carcinoma (MCC). Continue reading

Diffuse Gastric Cancer is Associated with Elevated GDF15 – Kristen D. De Wilde, Contributor

About 90% of stomach tumors are adenocarcinomas, which are subdivided into two main histologic types: (1) well-differentiated or intestinal type (IGC), and (2) undifferentiated or diffuse type (DGC). The intestinal type is related to corpus-dominant gastritis with gastric atrophy and intestinal metaplasia, whereas the diffuse type usually originates in pangastritis without atrophy. Diffuse gastric cancer (DGC) differs from the more common intestinal (IGC) type in that the former is less differentiated, has a poorer prognosis, and occurs more frequently in younger patients. Continue reading

Gastric Cancer Monoclonal Antibody Against Specific Target Shows Promise in Phase 2b Study

In a phase II randomized trial, adding IMAB362 to standard chemotherapy increased progression-free survival (PFS) and overall survival (OS) by about 50% compared with the standard treatment alone. Continue reading